- Report
- March 2024
- 197 Pages
Global
From €3237EUR$3,374USD£2,788GBP
€3597EUR$3,749USD£3,098GBP
- Report
- April 2024
- 138 Pages
Global
From €3741EUR$3,899USD£3,222GBP
- Report
- August 2023
- 166 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1919EUR$2,000USD£1,653GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1199EUR$1,250USD£1,033GBP
- Report
- August 2023
- 80 Pages
Global
From €3790EUR$3,950USD£3,264GBP
- Report
- October 2023
- 188 Pages
Global
From €4701EUR$4,900USD£4,049GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1439EUR$1,500USD£1,240GBP
- Report
- March 2024
- 200 Pages
Global
From €3982EUR$4,150USD£3,430GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4749EUR$4,950USD£4,091GBP
- Report
- January 2019
- 145 Pages
Global
From €5709EUR$5,950USD£4,917GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- January 2022
- 60 Pages
Global
From €3790EUR$3,950USD£3,264GBP
- Report
- January 2022
- 60 Pages
Global
From €3790EUR$3,950USD£3,264GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- November 2020
- 101 Pages
Global
€21109EUR$22,000USD£18,181GBP
- Report
- August 2022
Global
From €758EUR$790USD£653GBP
- Report
- May 2022
- 471 Pages
Global
From €2399EUR$2,500USD£2,066GBP
- Report
- March 2022
- 1284 Pages
Global
From €2399EUR$2,500USD£2,066GBP
- Clinical Trials
- November 2021
- 259 Pages
Global
From €2399EUR$2,500USD£2,066GBP
The Hypercholesterolemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on the treatment of high cholesterol levels. Hypercholesterolemia drugs are used to reduce the amount of cholesterol in the blood, which can help reduce the risk of heart attack and stroke. These drugs are typically prescribed to patients with high cholesterol levels, or those at risk of developing cardiovascular disease. Commonly prescribed drugs include statins, bile acid sequestrants, fibrates, and cholesterol absorption inhibitors.
The Hypercholesterolemia Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Sanofi, AstraZeneca, Novartis, and Bristol-Myers Squibb. Show Less Read more